These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 31527212)
1. Leptomeningeal involvement by prostate carcinoma an ominous head of a well-known Hydra. Tawadros F; Manthri S; Zayko M; Chakraborty K BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31527212 [TBL] [Abstract][Full Text] [Related]
2. Leptomeningeal metastasis from prostate cancer. Cante D; Franco P; Sciacero P; Girelli G; Casanova Borca V; Pasquino M; Migliaccio F; Tofani S; Grassi L; Marra A; Ozzello F; La Porta MR; Ricardi U Tumori; 2013; 99(1):6e-10e. PubMed ID: 23549020 [TBL] [Abstract][Full Text] [Related]
3. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931 [TBL] [Abstract][Full Text] [Related]
4. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM; Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888 [TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038 [TBL] [Abstract][Full Text] [Related]
7. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061 [TBL] [Abstract][Full Text] [Related]
8. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735 [TBL] [Abstract][Full Text] [Related]
9. Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review. Cursano MC; Iuliani M; Casadei C; Stellato M; Tonini G; Paganelli G; Santini D; De Giorgi U Crit Rev Oncol Hematol; 2020 Feb; 146():102864. PubMed ID: 31986318 [TBL] [Abstract][Full Text] [Related]
10. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report. Kosaka T; Hongo H; Oya M BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946 [TBL] [Abstract][Full Text] [Related]
11. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated? Serretta V; Valerio MR; Costa R; Tripoli V; Murabito A; Princiotta A; Scalici Gesolfo C; Borsellino N; Verderame F; Gebbia V; Licari M; Sanfilippo C; Urol Oncol; 2019 Dec; 37(12):964-969. PubMed ID: 31601517 [TBL] [Abstract][Full Text] [Related]
12. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. Kobayashi K; Okuno N; Arai G; Nakatsu H; Maniwa A; Kamiya N; Satoh T; Kikukawa H; Nasu Y; Uemura H; Nakashima T; Mikami K; Iinuma M; Tanabe K; Furukawa J; Kobayashi H Jpn J Clin Oncol; 2021 Apr; 51(4):544-551. PubMed ID: 33324967 [TBL] [Abstract][Full Text] [Related]
14. Interim Results From ERADICATE: An Open-Label Phase 2 Study of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects With Symptomatic Bone Metastases. Clin Adv Hematol Oncol; 2016 Apr; 14(4 Suppl 5):3-7. PubMed ID: 27167841 [No Abstract] [Full Text] [Related]
15. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529 [TBL] [Abstract][Full Text] [Related]
17. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine]. Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460 [TBL] [Abstract][Full Text] [Related]
18. De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All? Iacovelli R; Ciccarese C; Mosillo C; Tortora G Clin Genitourin Cancer; 2018 Dec; 16(6):482-484. PubMed ID: 30139716 [TBL] [Abstract][Full Text] [Related]
19. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511 [TBL] [Abstract][Full Text] [Related]
20. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases. Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]